Adjunctive Medications for Treatment-Resistant Depression
For adults with treatment-resistant major depressive disorder who have failed adequate trials of at least two antidepressants, aripiprazole or quetiapine are the most evidence-based adjunctive medication options, with aripiprazole being FDA-approved specifically for this indication and generally better tolerated than quetiapine. 1, 2
Primary Adjunctive Medication Options
First-Line Augmentation Agents
Atypical Antipsychotics are the most robustly studied adjunctive treatments:
Aripiprazole (FDA-approved for adjunctive MDD treatment)
- Dosing: 2-5 mg/day, typically starting at 2-3 mg
- Most robust evidence from multiple large-scale RCTs 2
- Lower weight gain risk compared to other atypicals
- Main concern: akathisia (though usually mild-moderate and rarely leads to discontinuation) 2
- Demonstrated clinically meaningful efficacy when added to ongoing antidepressants 1, 2
Quetiapine
Brexpiprazole (FDA-approved)
- Dosing: 2-3 mg once daily
- Similar efficacy to aripiprazole with potentially lower akathisia risk 3
- Newer agent with growing evidence base
Second-Line Augmentation Options
Lithium
- Demonstrated efficacy (OR 1.56) but less robust than atypical antipsychotics 1
- Requires monitoring (renal function, thyroid, levels)
- Higher side effect burden limits tolerability 1
Thyroid Hormone (T3)
- Evidence shows efficacy (OR 1.84) 1
- Less robust data than aripiprazole/quetiapine
- Consider particularly in patients with subclinical hypothyroidism
Buspirone
- Off-label option with some supporting evidence 4
- Generally well-tolerated
- Less robust efficacy data than atypical antipsychotics
Clinical Decision Algorithm
Step 1: Confirm True Treatment Resistance
- Verify adequate antidepressant trials (appropriate dose, duration 6-8 weeks minimum) 5
- Rule out pseudo-resistance from non-adherence or inadequate dosing 6
- Assess for comorbid conditions affecting response
Step 2: Choose Augmentation Strategy
Start with aripiprazole 2-3 mg daily as first-line augmentation because:
- FDA-approved indication
- Most robust evidence base 1, 2
- Better tolerability than quetiapine
- Lower metabolic risk than other atypicals
Alternative: Brexpiprazole 2-3 mg if:
- Patient experienced akathisia with aripiprazole previously
- Preference for potentially lower activation side effects 3
Consider quetiapine only if:
- Aripiprazole/brexpiprazole failed or not tolerated
- Patient needs sedation for comorbid insomnia
- Accept higher metabolic monitoring burden
Step 3: Monitor Response
- Assess within 1-2 weeks for tolerability 5
- Evaluate efficacy at 4-6 weeks
- Continue monitoring for metabolic effects with atypical antipsychotics (weight, glucose, lipids)
Important Caveats
Tolerability Trade-offs: While aripiprazole and quetiapine show the strongest efficacy, they carry significant side effect burdens. Quetiapine causes more sedation and metabolic effects (OR 3.85 for discontinuation due to side effects), while aripiprazole causes more akathisia 1. Discuss these specific risks before initiating.
Duration of Treatment: If augmentation achieves remission, continue for 4-9 months minimum; patients with multiple prior episodes may need indefinite treatment 5.
Alternative Strategies: The evidence does not clearly favor augmentation over switching antidepressants 5. However, augmentation with atypical antipsychotics has more robust evidence than most switching strategies 1.
Emerging Options: Esketamine (intranasal) and IV ketamine are FDA-approved for treatment-resistant depression but are typically reserved for patients who have failed multiple augmentation strategies 6, 7.
Off-Label Limitations: While lithium, buspirone, stimulants, and thyroid hormone are used off-label, their evidence is less robust than atypical antipsychotics 4, 1. Reserve these for patients who cannot tolerate or have failed atypical antipsychotic augmentation.